Case number 1:21-cv-00389
Biogen Inc. et al v. Teva Pharmaceuticals Development Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 8, 2021 | 27 | Patent/Trademark Report to Commissioner (3) Docket Text: Report to the Commissioner of Patents and Trademarks. (ntl) (Main Document 27 replaced on 10/8/2021) (ntl). |
| Oct 8, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Redacted version of Stipulation of Dismissal added to D.I. [27] per request of counsel. (ntl) |
| Oct 8, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [25] Stipulation of Dismissal filed by Teva Pharmaceuticals Development Inc., ***Civil Case Terminated. Signed by Judge Leonard P. Stark on 10/8/21. (ntl) |
| Oct 6, 2021 | 26 | Redacted Document (2) Docket Text: REDACTED VERSION of [25] Stipulation of Dismissal by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH. (Tigan, Jeremy) |
| Sep 28, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [24] STIPULATION TO EXTEND TIME for the (i) Parties to Exchange Initial Disclosures and Delaware ESI Paragraph 3 Initial Disclosures, and (ii) Plaintiffs' Identification of Accused Products and Asserted Patents to October 11, 2021 and October 18, 2021 filed by Biogen Swiss Manufacturing GmbH, Alkermes Pharma Ireland Limited, Biogen Inc. Signed by Judge Leonard P. Stark on 9/28/21. (ntl) |
| Sep 27, 2021 | 24 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for the (i) Parties to Exchange Initial Disclosures and Delaware ESI Paragraph 3 Initial Disclosures, and (ii) Plaintiffs' Identification of Accused Products and Asserted Patents to October 11, 2021 and October 18, 2021, respectively - filed by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH. (Tigan, Jeremy) |
| Sep 16, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: If, during the pendency of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Hall, they should contact chambers by e-mail at Cailah_Garfinkel@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Hall regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. In addition, Judge Hall may in the future enter a sua sponte order setting an ADR teleconference. ORDERED by Judge Jennifer L. Hall on 9/16/2021. (ceg) |
| Sep 16, 2021 | 22 | Scheduling Order (15) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 7/13/2022. Status Report due by 8/25/2022. Joint Claim Construction Brief due by 5/11/2022. A Markman Hearing is set for 5/26/2022 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 3/24/2023. A Final Pretrial Conference is set for 3/31/2023 at 01:00 PM in Courtroom 6B before Judge Leonard P. Stark. A 5-day Bench Trial is set for 4/10/2023 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 9/15/21. (ntl) |
| Sep 16, 2021 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Jennifer L. Hall for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf (Taylor, Daniel) |
| Sep 13, 2021 | 21 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Set of Interrogatories to Defendant Teva Pharmaceuticals Development Inc. and (2) Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant Teva Pharmaceuticals Development Inc. filed by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH.(Tigan, Jeremy) |
| Sep 9, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Sharon Lin for Teva Pharmaceuticals Development Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Sep 3, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [20] MOTION for Pro Hac Vice Appearance of Attorney Sharon Lin filed by Teva Pharmaceuticals Development Inc. Signed by Judge Leonard P. Stark on 9/3/21. (ntl) |
| Sep 2, 2021 | 20 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Sharon Lin - filed by Teva Pharmaceuticals Development Inc.. (Keller, Karen) |
| Sep 2, 2021 | 19 | Proposed Order (17) Docket Text: PROPOSED ORDER Scheduling Order (Agreed Upon) by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH. (Tigan, Jeremy) |
| Aug 19, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal, including a proposal for the length and timing of trial, to the Court no later than September 2, 2021. The parties are to review the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, New Patent Procedures). ORDERED by Judge Leonard P. Stark on 8/19/21. (ntl) |
| Jul 9, 2021 | 17 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove David J. Lehr as co-counsel. Reason for request: leaving the firm. (Tigan, Jeremy) |
| Jun 17, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Maureen L. Rurka and George C. Lombardi for Teva Pharmaceuticals Development Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Jun 17, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [16] MOTION for Pro Hac Vice Appearance of Attorney Maureen L. Rurka and George C. Lombardi filed by Teva Pharmaceuticals Development Inc. Signed by Judge Leonard P. Stark on 6/17/21. (ntl) |
| Jun 16, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Maureen L. Rurka and George C. Lombardi - filed by Teva Pharmaceuticals Development Inc.. (Hoeschen, Nathan) |
| Jun 11, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [15] MOTION for Pro Hac Vice Appearance of Attorney John R. McNair and Noorossadat Torabi filed by Teva Pharmaceuticals Development Inc. Signed by Judge Leonard P. Stark on 6/11/21. (ntl) |
| Jun 11, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Noorossadat Torabi and John R. McNair for Teva Pharmaceuticals Development Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Jun 11, 2021 | 15 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney John R. McNair and Noorossadat Torabi - filed by Teva Pharmaceuticals Development Inc.. (Hoeschen, Nathan) |
| Jun 7, 2021 | 14 | Answer to Counterclaim (15) Docket Text: ANSWER to [11] Answer to Complaint, Counterclaim -- Answer to Counterclaims -- by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH.(Blumenfeld, Jack) |
| May 24, 2021 | 13 | Notice (Other) (3) Docket Text: NOTICE of Change of Address for Latham & Watkins LLP by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH (Tigan, Jeremy) |
| May 17, 2021 | 12 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals Development Inc. filed by Teva Pharmaceuticals Development Inc.. (Hoeschen, Nathan) |
| May 17, 2021 | 11 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH by Teva Pharmaceuticals Development Inc..(Hoeschen, Nathan) |
| Apr 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Benjamin J. Behrendt, Adam L. Perlman, Arlene L. Chow, Ernest Yakob, Michelle L. Ernst, Jacob T. Whitt, David J. Lehr for Alkermes Pharma Ireland Limited, for Biogen Inc., for Biogen Swiss Manufacturing GmbH added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Mar 30, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [10] STIPULATION TO EXTEND TIME answer, move, or otherwise respond to the complaint to May 17, 2021 filed by Teva Pharmaceuticals Development Inc.; [9] MOTION for Pro Hac Vice Appearance of Attorney Arlene L. Chow, Ernest Yakob, Michelle L. Ernst, Jacob T. Whitt, Adam L. Perlman, Benjamin J. Behrendt and David J. Lehr filed by Biogen Swiss Manufacturing GmbH, Alkermes Pharma Ireland Limited, Biogen Inc. Signed by Judge Leonard P. Stark on 3/30/21. (ntl) |
| Mar 24, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Mar 23, 2021 | 10 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME answer, move, or otherwise respond to the complaint to May 17, 2021 - filed by Teva Pharmaceuticals Development Inc.. (Keller, Karen) |
| Mar 19, 2021 | 9 | Motion for Leave to Appear Pro Hac Vice (9) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Arlene L. Chow, Ernest Yakob, Michelle L. Ernst, Jacob T. Whitt, Adam L. Perlman, Benjamin J. Behrendt and David J. Lehr - filed by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH. (Blumenfeld, Jack) |
| Mar 17, 2021 | 1 | Main Document (13) Docket Text: COMPLAINT filed against Teva Pharmaceuticals Development Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3572892.) - filed by Biogen Swiss Manufacturing GmbH, Biogen Inc., Alkermes Pharma Ireland Limited. (Attachments: # (1) Exhibit A-C, # (2) Civil Cover Sheet)(mal) |
| Mar 17, 2021 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Biogen Swiss Manufacturing GmbH, Biogen Inc., Alkermes Pharma Ireland Limited. Teva Pharmaceuticals Development Inc. served on 3/17/2021, answer due 4/7/2021. (Blumenfeld, Jack) |
| Mar 17, 2021 | 7 | Summons Issued - Electronic (2) Docket Text: Summonses Issued (please complete the top portion of the form and print out for use/service). (mal) |
| Mar 17, 2021 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biogen MA Inc., Corporate Parent Biogen Swiss Investments GmbH, Corporate Parent Biogen U.S. Corporation for Biogen Swiss Manufacturing GmbH. Biogen Inc. is apublicly held corporation that directly or indirectly owns 10% or more of the stock of Biogen SwissManufacturing GmbH - filed by Biogen Inc., Biogen Swiss Manufacturing GmbH. (mal) |
| Mar 17, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alkermes plc for Alkermes Pharma Ireland Limited. T. Rowe Price Associates, Inc., whose parent company, T. Rowe Price Group, Inc. is a publicly held corporation, owns 10% or more of Alkermes plcs stock - filed by Alkermes Pharma Ireland Limited. (mal) |
| Mar 17, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,669,281 ;9,090,558 ;10,080,733. (mal) |
| Mar 17, 2021 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/03/2021. Date of Expiration of Patent: 09/20/2033.Thirty Month Stay Deadline: 8/3/2023. (mal) |
| Mar 17, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Mar 17, 2021 | 1 | Civil Cover Sheet (2) |
| Mar 17, 2021 | 1 | Exhibit A-C (105) |
| Mar 17, 2021 | 1 | Complaint* (1) |
